Skip to main content
Tanvex BioPharma, Inc. logo

Tanvex BioPharma, Inc. — Investor Relations & Filings

Ticker · 6541 ISIN · KYG8676P1037 TW Manufacturing
Open in API
Filings indexed 20 across all filing types
Latest filing 2026-05-13 Regulatory Filings
Country TW Taiwan
Listing TW 6541

About Tanvex BioPharma, Inc.

https://www.tanvex.com

Tanvex BioPharma, Inc. specializes in the research, development, manufacturing, and commercialization of biosimilars and innovative biologics. The company operates a vertically integrated model encompassing cell line development, process optimization, and clinical to commercial-scale production. Its portfolio focuses on biosimilars for oncology and supportive care, alongside emerging Antibody-Drug Conjugate (ADC) programs. Tanvex provides comprehensive Contract Development and Manufacturing Organization (CDMO) services, offering a unified platform that supports early-stage development through to commercial manufacturing. By maintaining GMP-compliant facilities and achieving regulatory approval for its biosimilar products, the company delivers end-to-end solutions aimed at increasing the accessibility of safe and effective treatments in international markets.

Recent filings

Filing Released Lang Actions
115年05月僑外投資持股
Regulatory Filings Classification · 78% confidence The document is a regulatory disclosure from Taiwan’s Public Information Observatory detailing the shareholding statistics of overseas Chinese, foreign, and Mainland China investors by category, as of a shareholders’ meeting. It contains actual table data on share counts rather than announcing the publication of a larger report or describing a corporate action like a dividend, capital change, M&A, or director transaction. It does not fit any more specific category, so it should be classified under the fallback “Regulatory Filings” (RNS).
2026-05-13 Chinese
公告本公司董事會通過115年第一季合併財務報告
Interim / Quarterly Report Classification · 87% confidence The document is a mandatory disclosure by a listed company (Taiwan market) announcing that its Board of Directors approved the Q1 consolidated financial report for the fiscal period 115/01/01–115/03/31. It provides actual interim financial data (revenues, profits/losses, assets, liabilities, equity, EPS) rather than merely linking or certifying a report. Therefore, it is a substantive Interim/Quarterly Report. Q1 2026
2026-05-12 Chinese
公告本公司內部稽核主管異動
Board/Management Information Classification · 95% confidence The document is a corporate announcement from listed company 6541 TaiFu-KY regarding a change in its internal audit head (senior management). It details the outgoing and incoming personnel, effective date, and nature of the personnel change. This clearly matches the “Board/Management Information” category (MANG) for announcements of changes in senior management.
2026-05-12 Chinese
公告本公司115年第一季合併財務報告董事會召開日期
Regulatory Filings
2026-05-04 Chinese
115年年報及股東會資料 — 2026_6541_20260604FE2.pdf
Regulatory Filings
2026-05-04 Chinese
115年年報及股東會資料 — 2026_6541_20260604F13.pdf
Regulatory Filings
2026-05-04 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.